Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Benign Versus Malignant Causes of Intussuception in Adults

NCT07238166 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-12-01
Last updated
2025-11-20

Condition(s) studied

Intussusception (IS)

Investigational drug(s) / intervention(s)

surgical resection and histopathological examination

surgical resection and histopathological examination: Adult patient diagnosed with intussusception will undergo surgical resection of affected bowel segment under general anathesia . the resected specimens will be sent for histopathological evalution to determine the underlying cause , whether benign (e.g lipoma , polyp )or malignant (e.g adenocarcinama , lymphoma ). operative finding , postoperative outcome , and pathology results will be recorded and analyzed

Study summary

The aim of this study is to evaluate adult intussecption :

* Prevalence of benign vs malignant causes.
* Distribution by anatomical type.
* Clinical presentation patterns.
* Diagnostic accuracy of imaging.
* Surgical approach and outcomes.
* Length of hospital stay, complications, recurrence

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
a. Inclusion criteria: * Age ≥ 19 years. • Confirmed diagnosis of intussusception by: Imaging (CT , ultrasound , or barium studies) Intraoperative findings, * Patients managed surgically with documented follow-up and final diagnosis. b. Exclusion criteria: * Patients with incomplete records or lost to follow-up * Intussusception diagnosed radiologically but resolved spontaneously without confirmatory intervention or follow-up

Primary outcome measure(s)

  • prevalence of benign versus malignant causes — 2 weeks after surgical resection
    Histopathological examination of resected bowel specimens will determine whether the cause of intussusception is benign (e.g., lipoma, polyp) or malignant (e.g., adenocarcinoma, lymphoma). The frequency and percentage of each category will be calculated

Trial sites (1)

FacilityCityRegionStatus
Department of general surgury Assiut uneversity hospital Asyut Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07238166 on ClinicalTrials.gov ↗ ← All trials in Egypt